Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Novartis receives psoriatic arthritis backing for Cosentyx from NICE

Novartis receives psoriatic arthritis backing for Cosentyx from NICE

20th April 2017

Novartis has announced that its drug Cosentyx has been approved for routine NHS use in England and Wales as a treatment for psoriatic arthritis.

The National Institute for Health and Care Excellence (NICE) has published a positive final appraisal determination backing the use of the secukinumab therapy among adults with active and progressive psoriatic arthritis.

It is recommended for use in patients with peripheral arthritis with three or more tender or swollen joints who have not responded to adequate trials of at least two standard disease-modifying antirheumatic drugs.

Dimitrios Georgiopoulos, ‎Novartis' chief scientific officer in the UK, said: "The NICE recommendation recognises the clinical importance of secukinumab, which has the potential to be the new standard of care for patients living with psoriatic arthritis."

Cosentyx is the first in a class of medicines called IL-17 inhibitors to be recommended in this setting. The targeted biologic therapy works by selectively binding to IL-17A to prevent it from causing inflammation.

It has already been approved by NICE for the treatment of moderate to severe plaque psoriasis and active ankylosing spondylitis.

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.ADNFCR-8000103-ID-801834917-ADNFCR

We have hundreds of jobs available across the Healthcare industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.